Drugs / AB-free kava
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07219186 | Apr 2026 → Mar 2027 expected | sleep disorder | University of Florida | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05814055 | Jun 2024 → Jan 2027 expected | — | University of Florida | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB-free kava | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05814055 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “a traditional plant-based supplement” NCT07219186 ↗ |
| Route | Oral | “Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 4 weeks.” NCT05814055 ↗ |